Northern Oesophago Gastric Cancer Unit MDT data NECN Audit Meeting – 6 th November 2013.

Slides:

Advertisements

Similar presentations

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.

Advertisements

Implementing NICE guidance

Be Clear on Cancer Regional Oesophageal Cancer Awareness Campaign November 2013 Jo Preston Network Delivery Manager Northern Strategic Clinical Networks.

National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons.

NPCA data submission and reporting

Advances and Emerging Therapy for Lung Cancer

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Cornelis J.H. van de Velde, MD, PhD,FRCPS(hon)FACS(hon) Professor of Surgery President ECCO - the European Cancer Organization Past-President European.

North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.

Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.

National Oesophago–Gastric Cancer Audit Comparing local and national figures.

CNS: Malignant Glioma Patient Pathway Project Kerry Mackenzie, Project Officer, WCMICS, Victoria; Dr Kate Drummond, Neurosurgeon, Project.

March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.

Oesophageal Cancer. -improving outcomes. Anil Kaul Consultant General and Upper GI Surgery St Helens and Knowsley Teaching Hospitals NHS Trust.

S Strong 1,2, NS Blencowe 1,2,T Fox 1, C Reid 3, T Crosby 4, H.Ford 5, J M Blazeby 1,2 1 School of Social and Community Medicine, Canynge Hall, University.

Pediatric Proton Therapy in the United States: Patterns of Care 2013 Danny Indelicato, MD Andrew Chang, MD.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Upper gastrointestinal cancers

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

Upper GI Disease Where we are Dr Gary Mackenzie Consultant Gastroenterologist.

Northern Region Colorectal Cancer Audit (NORCCAG) Colorectal NSSG – Audit meeting 1 st April 2006 – 31 st July 2010 Dorothy Simms – Audit Co-ordinator.

National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.

Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.

Clinical T1 Cancers S Wahed OG NSSG Audit Day 6 November 2013.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Skin Cancer Network Group Audit of Clinical Performance Indicators: Data quality and treatment quality Anna Murray BSc Cancer Information Analyst

1 Recent trends in colorectal cancer in Norway: incidence, management and outcomes Arne Wibe, MD, PhD Professor of Surgery St. Olavs Hospital Trondheim,

NSSG OG AUDIT DAY 2012 South Tees Hospitals Foundation Trust Sam Dresner, Consultant Surgeon Helen Wescott, OG Cancer CNS.

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

NSSG OG AUDIT DAY 2013 South Tees Hospitals Foundation Trust Sam Dresner, Consultant Surgeon Helen Wescott, OG Cancer CNS.

The Effect of Obesity on the Radicality of Subtotal Oesophagectomy for Oesophageal Adenocarcinoma S Wahed, HV Jones, A Krishnan, J Shenfine, SM Griffin.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

The significance of extracapsular lymph node involvement in node- positive patients with adenocarcinoma of the distal oesophagus or gastro-oesophageal.

Northern Oesophago-Gastric Cancer Unit MDT meeting NECN Audit day 2012 Helen Jaretzke, Angie Tate, Jon Shenfine, Paula Brookes, Leigh-Anne Phillips, Gillian.

Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?

Newcastle upon Tyne Hospitals NHS Foundation Trust Audit results for NAOG meeting 19 April 2013 The Newcastle upon Tyne Hospitals NHS Foundation Trust.

P53 adapted neoadjuvant therapy for esophageal cancer: Pilot study Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007.

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower.

LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.

Rachel Rowlands 17 th May  2012 Be Clear on Cancer campaign  Aims of the study  Methodology  Results  Conclusions  Limitations  Recommendations.

Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

Cancer Information Framework Initial feedback on NWCN LUCADA submission 2006 data Wednesday 20 th February, 2008 Linda Roberts, Cancer Information Specialist,

Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.

National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.

PathoSys ® NEPath Project Update 6 th September 2011.

Raising awareness of oesophageal cancer: The regional pilot Professor S. Michael Griffin Northern Oesophago-Gastric Cancer Unit Newcastle upon Tyne.

What data are collected? How, and who by? Karen Graham and Barry Plewa.

TRIAL PARTICIPATION IN THE OVER 60s: A RE-AUDIT OF THE MANAGEMENT OF AML IN THE SOUTH WEST OF ENGLAND South West Cancer Intelligence Service

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

NORTHUMBRIA PANCREATIC CARCINOMAS – Jan 2013 – Jan 2014 Number of new pancreatic carcinoma referrals56 Number of case discussed in local MDT55 Number of.

What data are collected? How, and who by?. It’s complicated… ONS data.

Oesophago–Gastric Cancer Audit

Oesophago–Gastric Cancer

National Oesophago–Gastric Cancer Audit 2015.

Risk Stratification (Miettinen) Mutational status results (N=50)

HANA Audit Update for SSG

Prognosis of younger patients in non-small cell lung cancer

Oesophago–Gastric Cancer

Oesophago–Gastric Cancer Audit

M.Boal; J. Batt; P. Wilkerson; D.R. Titcomb

Oesophago–Gastric Cancer

Pathway for patients with suspected Skin Cancer

Clinical activity in the last year at the BRI OG unit.

Pathway for patients with suspected Upper GI (OG) Cancer

Hannah Marder Cancer Manager UH Bristol

National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set

Neoadjuvant Adjuvant Curative Palliative

National Oesophago-Gastric Cancer Audit

Presentation transcript:

Northern Oesophago Gastric Cancer Unit MDT data NECN Audit Meeting – 6 th November 2013

Methods Patients discussed at weekly Newcastle Multi-disciplinary Team meeting in period January – December 2012 Excludes patients discussed by video-link to Sunderland Prospective data entry onto database - Dendrite Intended use: Local, Regional & National audit Research Data then exported onto Microsoft Excel for analysis

National Audit Programme The second Audit began collecting prospective data on patients (aged 18 years or over) diagnosed with invasive epithelial cancer of the oesophagus, gastro- oesophageal junction (GOJ) or stomach on or after 1 April Since 1 April 2012, the Audit has also included patients diagnosed with oesophageal high-grade glandular dysplasia (HGD). To allow this, a slightly revised dataset was implemented in April 2012.

National Audit 2013 – Resections by site

MDT Discussions n=1511 incl Carlisle 588 excl Carlisle

New discussions N = cancers Other incl. – GISTs, HGD, LGD, Surveillance pts, & referred onto another MDT

New OG neoplasm n=463

Number of MDT Discussions N=588 – New Discussions Excl. 86 Carlisle pts Median discussion: 2

Age

Carlisle Discussions

New referrals to MDT by site n=450 vs. 324 vs. 408 vs 467 vs 437 vs 463 excl Carlisle pts – positive cancers only

Intention to treat by site No action – incl. Benign, Best supportive care & referral onto other MDT’s Friday MDT’s only

Oesophageal Cancer: (2012) Histological subtype Other incl. – Carcinoid, Leioyoma, melanoma, benign

Oesophageal Cancer: Treatment intent by histological subtype

Oesophageal cancer: Curative treatment intent

Actual Resections - Pos Cancers only

Procedures 2012 CompletedIncompl.30 day90 dayComps 3+ Accordion Oesophagectomy Total Gastrectomy Subtotal Gastrectomy Lesser resection EMR35N/A000

Morbidity/Complications note: 30 day Mort all complications incl. n= n= n= N=

Pathological Stage by subtype Excl. Carcinoid’s & Leioyoma’s excluded, 8 open and close excluded

Oesophageal Cancer: Treatment change Intended TreatmentTreatment Changen Neoadjuvant + SurgeryUnfit for surgery3 Neoadjuvant + SurgeryProgression of disease, no surgery7 Neoadjuvant + SurgeryRIP (1 cycle)2 Neoadjuvant + SurgeryPatient declined2 SurgeryNot fit for surgery/patient declined2 Neoadjuvant + SurgeryShortened chemotherapy due to toxicity5 Neoadjuvant + SurgeryNo neoadjuvant given2 ChemoradiotherapyToxicity 1 pt did not complete chemo, although did complete radio. 1

Recruitment to trials Please note: Cougar 02 closed 30/04/12. Other trials had closed

UGI Two Week Waits day breaches: 14.5 (0.84%)

Refs- 2 Week Waits – Comparison by Year

Breaches - Comparison

Acknowledgements Helen JaretzkeNOGCU Data Manager Angie TateNOGCU Data Clerk Paula BrooksMDT Coordinator Jonathan StoddartNCCC Research Coordinator